Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
September 09, 2024 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
September 03, 2024 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 19, 2024 16:05 ET
|
Cue Biopharma, Inc.
BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
Cue Biopharma to Host Business Update Call and Webcast
August 13, 2024 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
July 25, 2024 16:05 ET
|
Cue Biopharma, Inc.
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company...
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
June 04, 2024 08:00 ET
|
Cue Biopharma, Inc.
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and...
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
June 03, 2024 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024 16:05 ET
|
Cue Biopharma, Inc.
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
May 08, 2024 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
May 07, 2024 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...